Deubiquitinating enzymes as oncotargets
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Urszula L. McClurg 1 and Craig N. Robson 1 1 Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne, UK Correspondence to: Craig N. Robson, email: // Keywords : deubiquitination, DUBs, cancer, epigenetics, chromatin, androgen receptor, histones Received : March 09, 2015 Accepted : April 08, 2015 Published : April 23, 2015 Abstract Carcinogenesis is a complex process tightly regulated at multiple levels by post-translational modifications. Epigenetics plays a major role in cancer development, all stable changes to the gene expression process that are not a result of a direct change in the DNA code are described as epigenetics. Epigenetic processes are regulated by post-translational modifications including ubiquitination which can directly affect either histones or transcription factors or may target their co-factors and interacting partners exerting an indirect effect. Deubiquitination of these target proteins is equally important and alterations in this pathway can also lead to cancer development, progression and metastasis. Only the correct, unaltered balance between ubiquitination and deubiquitination ensures healthy cellular homeostasis. In this review we focus on the role of deubiquitinating (DUB) enzymes in various aspects of epigenetics including the regulation of transcription factors, histone modifications, DNA damage repair pathways and cell cycle regulation. We discuss the impact of those processes on tumourigenesis and potential therapeutic applications of DUBs for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks
Burma, S., Chen, B. P., Murphy, M., Kurimasa, A., & Chen, D. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100466200 · Cited by 1,954 · cited 6×
“Usp3 associates with chromatin and deubiquitinates H2A at K13 and K15 and γH2AX at K118 and K119.”
InfluentialThe emerging complexity of protein ubiquitination
Komander, D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370937 · Cited by 821 · cited 1×
“The consequences of ubiquitination depend on the type of chains formed during the process [4].”
A dynamic role of HAUSP in the p53-Mdm2 pathway
Li, M., Brooks, C. L., Kon, N., & Gu, W. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00157-1 · Cited by 679 · cited 10×
“P53 can be directly deubiquitinated by Usp42 which reverses its ubiquitination by MDM2 [9].”
InfluentialUSP10 Regulates p53 Localization and Stability by Deubiquitinating p53
Yuan, J., Luo, K., Zhang, L., Cheville, J. C., & Lou, Z. (2010) · Cell · doi:10.1016/j.cell.2009.12.032 · Cited by 637 · cited 2×
“com/oncotarget allow its activity towards p53, the Usp10 protein needs to be phosphorylated at T42 and S337 by ATM, this occurs as a result of DNA damage and stabilises Usp10 allowing it to translocate to the nucleus and deubiquitinate p53 [67].”
Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.007 · Cited by 589 · cited 2×
“Usp7 HBX 19,818 and HBX 28,258 P5091 and P22077 Pimozide Usp47 Usp1, Usp2, Usp5, Usp8, Usp46 [93] [95], [96], [97] [87] Usp10 Spautin-1 Usp13 [77]”
Zhang, X.-Y., Varthi, M., Sykes, S. M., Phillips, C., Warzecha, C., Zhu, W., Wyce, A., Thorne, A. W., Berger, S. L., & McMahon, S. B. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.015 · Cited by 427 · cited 18×
“54. van der Knaap JA, Kumar BR, Moshkin YM, Langenberg K, Krijgsveld J, Heck AJ, Karch F and Verrijzer CP. GMP synthetase stimulates histone H2B deubiquitylation by the epigenetic silencer USP7.”
InfluentialLin, Z., Yang, H., Kong, Q., Li, J., Lee, S.-M., Gao, B., Dong, H., Wei, J., Song, J., Zhang, D. D., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.03.024 · Cited by 315 · cited 1×
“Additionally, Usp22 directly deubiquitinates TRF1 (TBP(TATA box-binding protein)-related factor 1) to regulate the transcription of cell cycle and apoptosis genes [60] and inhibits the transcriptional activity of p53 by deubiquitinating SIRT1 histone deacetylase [61] and by regulating MDMX stability [62].”
Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme.
Reverdy, C., Conrath, S., Lopez, R., Planquette, C., Atmanene, C., Collura, V., Harpon, J., Battaglia, V., Vivat, V., Sippl, W., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.02.007 · Cited by 270 · cited 3×
“Usp7 HBX 19,818 and HBX 28,258 P5091 and P22077 Pimozide Usp47 Usp1, Usp2, Usp5, Usp8, Usp46 [93] [95], [96], [97] [87] Usp10 Spautin-1 Usp13 [77]”
USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan, Y.-H., Cheng, J., Vasudevan, S. A., Dou, J., Zhang, H., Patel, R. H., Ma, I. T., Rojas, Y., Zhao, Y., Yu, Y., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.400 · Cited by 199
Cited by
The role of ubiquitin-specific peptidases in cancer progression
Young, M.-J., Hsu, K.-C., Lin, T. E., Chang, W.-C., & Hung, J.-J. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0522-0 · Cited by 164
Cellular and disease functions of the Prader–Willi Syndrome gene MAGEL2
Tacer, K. F., & Potts, P. R. (2017) · Biochemical Journal · doi:10.1042/bcj20160616 · Cited by 81
Hernández-Pérez, S., Cabrera, E., Salido, E., Lim, M., Reid, L., Lakhani, S. R., Khanna, K. K., Saunus, J. M., & Freire, R. (2017) · Oncogene · doi:10.1038/onc.2017.21 · Cited by 61
Wang, L., Hu, T., Shen, Z., Zheng, Y., Geng, Q., Li, L., Sha, B., Li, M., Sun, Y., Guo, Y., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05341-3 · Cited by 45
“Abnormal DUB activity is associated with many diseases, especially tumor progression [8, 9].”
BackgroundInhibition of USP1, a New Partner of Bcr-Abl, Results in Decrease of Bcr-Abl Level in K562 Cells
Antonenko, S. V., & Telegeev, G. D. (2023) · Experimental Oncology · doi:10.32471/exp-oncology.2312-8852.vol-42-no-2.14533 · Cited by 19
Metadata
- Authors
- McClurg, U. L., & Robson, C. N.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-04-23
- Volume
- 6
- Issue
- 12
- Pages
- 9657-9668
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1907342860
- Cited by
- 100
- References
- 9
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.